首页|期刊导航|甘肃医药|乳腺癌诊疗规范化系统应用分析

乳腺癌诊疗规范化系统应用分析OA

Application analysis of standardized diagnosis and treatment system for breast cancer

中文摘要英文摘要

目的:构建基于医院信息集成平台的乳腺癌诊疗规范化智能质控系统,实现诊疗全过程实时干预,量化评价该系统对临床质控指标、医师诊疗同质化、患者就医体验的改善效果,提升区域乳腺癌规范化诊疗管理水平.方法:依托HIS、LIS、RIS、EMR、病理等院内业务系统搭建乳腺癌规范化诊疗系统,内置指南知识库与实时质控规则引擎,具备智能提示、分级预警、质控评估、多维度数据统计分析功能.选取系统上线前647例、上线1 年后609例乳腺癌住院患者,对比术后病理TNM分期、首次治疗前临床TNM分期诊断率、非手术治疗前病理诊断、HER2 靶向匹配、腋窝淋巴结清扫充分 5 项核心质控指标;于系统上线 1 年后开展患者满意度问卷调查,从诊疗安全性、流程精简性、诊疗有效性与知情权3个维度评价就医体验.采用SPSS 26.0软件处理数据检验.结果:系统上线1年后,5项核心质控指标合格病例数均提升,组间对比差异具有统计学意义(P<0.05).满意度调查结果显示,患者各维度平均得分均>4.1分,认可类评价占比超80%,否定类评价低于2.5%,患者认可度高.同时系统可弥补不同年资医师诊疗水平差异,提升青年医师临床规范化诊疗能力,减轻临床文书与质控统计负担.结论:基于信息化集成的乳腺癌诊疗规范化系统可实现诊疗事前提醒、事中纠偏、事后追溯全流程闭环管理,有效统一不同医师诊疗标准,提升单病种质控指标达标率与诊疗同质化水平,优化患者就医体验,为区域肿瘤单病种标准化、长效化质控管理提供可复制的信息化解决方案.

Objective:To construct an intelligent quality control system for standardized diagnosis and treatment of breast cancer based on a hospital information integration platform,realize real-time intervention in the whole diagnosis and treatment process,quantitative-ly evaluate the improvement effect of the system on clinical quality control indicators,homogenization of physicians'diagnosis and treat-ment,and patients'medical experience,so as to improve the standardized diagnosis and treatment management level of regional breast can-cer.Methods:A standardized breast cancer diagnosis and treatment system was built relying on hospital business systems including HIS,LIS,RIS,EMR and the pathology system,with built-in guideline knowledge base and a real-time quality control rule engine,which integrat-ed functions of intelligent reminders,hierarchical early warning,quality control evaluation and multi-dimensional data statistical analysis.A total of 647 inpatients with breast cancer in January 2025(before system launch)and 609 in January 2026(one year after launch)were en-rolled.Five core quality control indicators including postoperative pathological TNM staging,clinical TNM staging before initial treatment,pathological diagnosis before non-surgical treatment,matching of HER2 targeted therapy and adequate axillary lymph node dissection were compared.SPSS 26.0 software was used for data processing.Patient satisfaction questionnaires were distributed one year after system launch to evaluate medical experience from three dimensions:treatment safety,streamlined workflow,treatment efficacy and informed consent.Results:One year after the system went online,the number of qualified cases of all five core quality control indicators increased significant-ly,with P<0.01,showing statistically significant differences.The results of the satisfaction survey showed that the average score of each di-mension was higher than 4.1 points,the proportion of positive feedback exceeded 80%,and negative feedback accounted for less than 2.5%,reflecting high recognition among patients.In addition,the system could make up for the difference in diagnosis and treatment ability among physicians with different seniorities,improve the standardized clinical ability of young doctors,and reduce the burden of clinical documents and quality control statistics.Conclusion:The information-based standardized diagnosis and treatment system for breast cancer can realize closed-loop management of pre-event reminders,intra-event corrections and post-event traceability.It can effectively unify the diagnosis and treatment standards of different physicians,improve the compliance rate of single-disease quality control indicators and homogenization of clinical practice,and optimize patients'medical experience.It provides a replicable information solution for standardized and long-term quality control management of regional single tumor diseases.

闫鹏飞;王军;白晓蓉;高晨;胡仪曼

中山大学附属肿瘤医院甘肃医院,甘肃 兰州 730050中山大学附属肿瘤医院甘肃医院,甘肃 兰州 730050中山大学附属肿瘤医院甘肃医院,甘肃 兰州 730050中山大学附属肿瘤医院甘肃医院,甘肃 兰州 730050中山大学附属肿瘤医院甘肃医院,甘肃 兰州 730050

医药卫生

乳腺癌规范化诊疗肿瘤质控系统临床决策支持医疗信息化单病种管理

standardized diagnosis and treatment of breast cancertumor quality control systemclinical decision supportmedical informatizationsingle-disease management

《甘肃医药》 2026 (5)

437-440,453,5

国家癌症中心抗肿瘤药物临床应用监测网支持项目(编号:DSS-YSF-2023013)

10.15975/j.cnki.1004-2725.2026.05.011

评论